Canaccord lowered the firm’s price target on Alnylam to $283 from $284 and keeps a Buy rating on the shares. The firm saidthe big news from ots Q4 report was the changes to HELIOS-B’s statistical analysis plan affecting both primary/secondary endpoint structure and the trial’s duration. These changes delay the readout to late June/early July.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on ALNY: